Ann: Extension Study Begins, Analysis Suggests Survival Benefit, page-141

I think the results on MND alone would need to be absolutely spectacular, as in no progression with treatment.
Then a few billion for MND alone is probably reasonable given other aquisitions in the space, pointed out by MT, where 500mUSD was low cae for a pre clinical drug.

If the results are ok but not blockbuster but slightly better than relyvrio and riluzole, perhaps worth a billion?

If results are ho hum then...no soup for you.

Here's to hoping we halt MND and sell the MND alone rights for 2 to 3 billion USD.

Wishful thinking but it's nice to dream.

If we go on to have a meaningful impact on Alzheimer's then I don't see a 5 billion USD+ price for that as being unreasonable, and theres your $10+ SP.

Still a long way off and all of this rides on the topline results this month. Blockbuster or just bust? Place your bets.